What Next For Cache Inc (CACH), Scientific Games Corp (SGMS), And XOMA Corp (XOMA)?
New York, NY – GDP INSIDER – 01/06/2014.
Cache Inc (NASDAQ:CACH) is obviously confronted by the challenges that are facing retailers everywhere in the country. The company cited weak store traffic and inventory issues among the challenges that have adversely impacted its performance in the recent quarters. However, according to CEO, Jay Margolis, there is imminent success, and they are working towards that.
Although Cache Inc (NASDAQ:CACH) has been closing stores as part of the efforts to remake itself, the company announced that it didn’t intend to close more stores for the balance of fiscal 2014. Instead, they will open new stores. As the company seeks to improve the performance of its brick-and-mortar stores, there are also deliberate efforts to increase online presence as more shoppers move to the Internet. Nonetheless, the company reported an adverse impact on its online campaign in 3Q because of a problem with its Web platform.
The management of Cache Inc (NASDAQ:CACH) admits that their performance has not been good enough in the past quarters, but the future remains bright for the company and its shareholders.
Scientific Games Corp (NASDAQ:SGMS)’s move to acquire Bally Technologies for $5.1 billion may have been one of the greatest decisions the company made in 2014. Therefore, starting this year, the company is expected to enjoy a wide range of benefits that include expanded geographical presence and operating efficiencies. In particular, the acquisition is expected to help Scientific Games expand its geographical footprint in Australia and save about $235 million in costs in the first year.
Scientific Games Corp (NASDAQ:SGMS) has also been adding highly qualified leaders to its board. The move that is expected also to help the company improve its performance, especially following a series of strategic acquisitions.
XOMA Corp (NASDAQ:XOMA) has its best bet in its drug candidate gevokizumab. However, the question now is how investors should view gevokizumab. One of the important things about the drug candidate is that it has a wide label indication, which means that it has the potential to attract respectable revenue even with a few successes.
Additionally, XOMA Corp (NASDAQ:XOMA)’s recent fundraiser means that the company now has the cash it needs to take care of the development of gevokizumab without much headache. As such, gevokizumab is a key catalyst that should concern investors playing XOMA.
UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.
UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.